 |
PDBsum entry 6nip
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Viral protein/immune system
|
PDB id
|
|
|
|
6nip
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
 |
Contents |
 |
|
|
|
|
|
|
|
|
|
|
|
221 a.a.
|
|
|
|
|
|
|
|
|
|
|
214 a.a.
|
|
|
|
|
|
|
|
|
|
|
399 a.a.
|
|
|
|
|
|
|
|
|
|
References listed in PDB file
|
|
|
Key reference
|
|
|
Title
|
|
Potent zika and dengue cross-Neutralizing antibodies induced by zika vaccination in a dengue-Experienced donor.
|
|
|
Authors
|
|
V.Dussupt,
R.S.Sankhala,
G.D.Gromowski,
G.Donofrio,
R.A.De la barrera,
R.A.Larocca,
W.Zaky,
L.Mendez-Rivera,
M.Choe,
E.Davidson,
M.K.Mccracken,
J.D.Brien,
P.Abbink,
H.Bai,
A.L.Bryan,
C.H.Bias,
I.M.Berry,
N.Botero,
T.Cook,
N.A.Doria-Rose,
A.G.I.Escuer,
J.A.Frimpong,
A.Geretz,
M.Hernandez,
B.S.Hollidge,
N.Jian,
K.Kabra,
D.J.Leggat,
J.Liu,
A.K.Pinto,
W.Rutvisuttinunt,
I.Setliff,
U.Tran,
S.Townsley,
B.J.Doranz,
M.Rolland,
A.B.Mcdermott,
I.S.Georgiev,
R.Thomas,
M.L.Robb,
K.H.Eckels,
E.Barranco,
M.Koren,
D.R.Smith,
R.G.Jarman,
S.L.George,
K.E.Stephenson,
D.H.Barouch,
K.Modjarrad,
N.L.Michael,
M.G.Joyce,
S.J.Krebs.
|
|
|
Ref.
|
|
Nat Med, 2020,
26,
228-235.
[DOI no: ]
|
|
|
PubMed id
|
|
|
|
|
|
|
|
|
Abstract
|
|
|
Zika virus (ZIKV) has caused significant disease, with widespread cases of
neurological pathology and congenital neurologic defects. Rapid vaccine
development has led to a number of candidates capable of eliciting potent
ZIKV-neutralizing antibodies (reviewed in refs. 1-3). Despite
advances in vaccine development, it remains unclear how ZIKV vaccination affects
immune responses in humans with prior flavivirus immunity. Here we show that a
single-dose immunization of ZIKV purified inactivated vaccine
(ZPIV)4-7 in a dengue virus (DENV)-experienced human elicited potent
cross-neutralizing antibodies to both ZIKV and DENV. Using a unique ZIKV
virion-based sorting strategy, we isolated and characterized multiple
antibodies, including one termed MZ4, which targets a novel site of
vulnerability centered on the Envelope (E) domain I/III linker region and
protects mice from viremia and viral dissemination following ZIKV or DENV-2
challenge. These data demonstrate that Zika vaccination in a DENV-experienced
individual can boost pre-existing flavivirus immunity and elicit protective
responses against both ZIKV and DENV. ZPIV vaccination in Puerto Rican
individuals with prior flavivirus experience yielded similar cross-neutralizing
potency after a single vaccination, highlighting the potential benefit of ZIKV
vaccination in flavivirus-endemic areas.
|
|
|
|
|
|
|
